Related Experiment Video
Updated: Aug 1, 2025
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Dual-Responsive Triple-Synergistic Fe-MOF for Tumor Theranostics
Zhiwei Chen1, Yaoji Sun1, Jiawei Wang1
1Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance Research, School of Electronic Science and Engineering, Xiamen University, Xiamen 361005, People's Republic of China.
Abstract:
The intelligent responsive drug delivery system has great application potential in cancer precision therapy. Although many antitumor methods have been developed based on drug delivery systems, most of them yet suffer from poor antitumor efficiency. In this project, a near-infrared and pH dual-response multimodal collaborative platform for diagnosis and treatment (PCN-DOX@PDA) was constructed. We used PCN-600 as a vehicle loaded with antineoplastic drugs and polydopamine (PDA). Under 633 nm laser irradiation, the ligand tetrakis(4-carboxyphenyl)porphyrin (TCPP) in PCN-600 can generate singlet oxygen (1O2) and kill tumor cells. PDA is used as photothermal agent of PTT. PCN-DOX@PDA achieves the intelligent release of antitumor drugs by responding to the weak acidity of the tumor microenvironment and thermal stimulation generated by NIR irradiation. In addition, since the central ion of PCN is Fe3+, PCN-DOX@PDA realizes the diagnosis and treatment of tumors through magnetic resonance imaging-mediated tumor chemotherapy and photothermal and photodynamic synergistic therapy. This triple synergistic strategy showed excellent biocompatibility and antitumor ability in in vivo experiments on a 4T1 tumor-bearing mouse model, indicating that PCN-DOX@PDA has a good development prospect in the field of precision cancer therapy and diversified biomedical applications.
Insights
A novel dual-responsive platform (PCN-DOX@PDA) enhances cancer therapy. This intelligent system combines chemotherapy, photothermal, and photodynamic treatments for improved antitumor efficiency and diagnosis.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Current cancer therapies often lack efficiency.
- Intelligent drug delivery systems show promise for precision cancer therapy.
- Developing multimodal platforms is crucial for enhanced treatment outcomes.
Purpose of the Study:
- To construct a near-infrared and pH dual-responsive multimodal platform (PCN-DOX@PDA) for cancer diagnosis and treatment.
- To investigate the synergistic effects of chemotherapy, photothermal therapy (PTT), and photodynamic therapy (PDT).
- To evaluate the platform's biocompatibility and antitumor efficacy in vivo.
Main Methods:
- Fabrication of PCN-600 loaded with doxorubicin (DOX) and polydopamine (PDA).
- Utilizing tetrakis(4-carboxyphenyl)porphyrin (TCPP) for photodynamic therapy (PDT) under 633 nm laser irradiation to generate singlet oxygen (¹O₂).
- Employing PDA as a photothermal agent for PTT and Fe³⁺ for magnetic resonance imaging (MRI).
Main Results:
- PCN-DOX@PDA demonstrated intelligent drug release in response to tumor microenvironment acidity and NIR-induced thermal stimulation.
- The triple synergistic therapy (chemotherapy, PTT, PDT) showed significant antitumor activity.
- In vivo experiments on 4T1 tumor-bearing mice confirmed excellent biocompatibility and antitumor efficacy.
Conclusions:
- The PCN-DOX@PDA platform offers a promising strategy for precision cancer therapy.
- This multimodal approach integrates diagnosis and treatment, enhancing therapeutic outcomes.
- The developed system has broad prospects for diversified biomedical applications in cancer treatment.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
